Save
Lymphocyte changes induces by alemtuzumab in multiple sclerosis patients
Author(s): ,
S. Medina
Affiliations:
Department of Immunology
,
S. Sainz de la Maza
Affiliations:
Department of Neurology, Ramón y Cajal Hospital, Madrid, Spain
,
N. Villarrubia
Affiliations:
Department of Immunology
,
J.C. Álvarez-Cermeño
Affiliations:
Department of Neurology, Ramón y Cajal Hospital, Madrid, Spain
,
E. Monreal
Affiliations:
Department of Neurology, Ramón y Cajal Hospital, Madrid, Spain
,
A. Tejeda-Velarde
Affiliations:
Department of Immunology
,
E. Rodríguez-Martín
Affiliations:
Department of Immunology
,
L. Costa-Frossard
Affiliations:
Department of Neurology, Ramón y Cajal Hospital, Madrid, Spain
L.M. Villar
Affiliations:
Department of Immunology
ECTRIMS Online Library. Medina S. Oct 12, 2018; 229050
Silvia Medina
Silvia Medina
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Abstract
Discussion Forum (0)
Rate & Comment (0)

Abstract: P1210

Type: Poster Sessions

Abstract Category: Therapy - Immunomodulation/Immunosuppression

Introduction: Alemtuzumab is a humanised monoclonal antibody that recognises CD52, a protein expressed on the surface of mature lymphocytes. It has been approved for the treatment of relapsing remitting multiple sclerosis (RRMS). Altrhough it has been postulated that it induce reprogramming of the abnormal immune response in MS, the particular changes in leucocyte subsets have not been fully ascertained.
Objective: To deepen the study of changes in blood immune cells induces by alemtuzumab in an exploratory cohort of MS patients.
Methods: We studied peripheral blood mononuclear cells of 8 patients diagnosed with RRMS and treated with this drug before treatment and after 12 months before the second cycle of alemtuzumab. We explored different CD4, CD8 T cell subsets, B cell subpopulations and monocytes and intracellular cytokine production.
Results: We observed a decrease in the total number of CD4+ T cells (p=0.03), regulatory T cells (p=0.03) and central memory CD4+ (p=0.01) and CD8+ (p=0.03) T cells. Numbers of plasmablasts were also decreased (p=0.01) and memory B cells (p=0.01) increased. Additionally, we observed an increase in number of regulatory NK cells (p=0.007) and a decrease in NKT cells (p=0.007). The production of GM-CSF by T cells (p=0.007 in CD8+ and p=0.01 in CD4+) and production of TNF-alfa by CD4+ T cells (p=0.007) and B cells (p=0.01) were also decreased. In addition, we quantified the production of different cytokines by measuring the mean fluorescence intensity (MFI) and observed a decrease in the production of GM-CSF by CD8+ T cells (p=0.007), and TNF-alfa by CD4+ T cells (p=0.01) and B cells (0.007).
Conclusions: Alemtuzumab treatment induces an increase in regulatory NK cells and a decrease in effector cells with the exception of memory B cells that increased with this treatment. We also observed a decrease in proinflamatory cytokine production.
Disclosure: S. Medina: Nothing to disclose. S. Sainz de la Maza: received payment for lecturing from Novartis, Biogen, Roche and Merck. N. Villarrubia: Nothing to disclose. J.C. Álvarez-Cermeño: received payment for lecturing or research grants from Merck, Novartis, Biogen, Roche, Bayer, Teva, and Sanofi-Genzyme. E. Monreal: Nothing to disclose. A. Tejeda-Velarde: Nothing to disclose. E. Rodríguez-Martín: Nothing to disclose. L. Costa-Frossard: received payment for lecturing from Novartis, Biogen, Roche, Bayer and Sanofi- Genzyme. L.M. Villar: received payment for lecturing or research grants from Merck, Novartis, Biogen, Roche and Sanofi- Genzyme.
Funding: FIS-PI15/00513 and RD16/0015/0001.

Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings